Reason: Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'
Distributed: Nationwide in the USAReason: Labeling: Not Elsewhere Classified: Back label states Each contains: cephalexin monohydrate, USP equivalent to 2.5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g
Distributed: Nationwide in the USAReason: Labeling: Not Elsewhere Classified: Front label states 100 Tablets instead of 100 ml and on the back label 'Each Tablet contains' instead of 'Each Bottle contains' No total dose per bottle listed should be 2.5 g'
Distributed: Nationwide in the USAReason: CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Distributed: US Nationwide.Reason: CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Distributed: US Nationwide.Reason: CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Distributed: US Nationwide.Reason: CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Distributed: US Nationwide.Reason: Lack of Assurance of Sterility: Complaints of syringe breakage
Distributed: USA nationwide.Reason: Out of Specification for active ingredient
Distributed: Distributed Nationwide in the USAReason: Out of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.
Distributed: Distributed Nationwide in the USA